Compare BioNTech SE - ADR (BNTX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Energy Select Sector SPDR Fund — how do they compare? BioNTech SE - ADR trades at $92.99 (market cap $23.31B), while Energy Select Sector SPDR Fund trades at $60.74. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | XLE | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | — |
52-Week High | $119.34 | $62.57 |
52-Week Low | $83.89 | $42.33 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
XLE trades at $60.47, up 0.47% with a bullish technical signal from moving averages. The ETF has rallied 40.52% over the past year, driven by strong oil prices and geopolitical tensions in the Middle East. Recent earnings from major holdings like ExxonMobil and Chevron showed profit surges, supporting the sector's momentum. Technical indicators show support at $59 and resistance at $61, with RSI readings in neutral territory suggesting room for further movement.
Outlook remains positive but faces geopolitical risks. The energy sector benefits from elevated oil prices and strong earnings, though concentration in a few large stocks and sensitivity to Middle East tensions present volatility. Analyst sentiment is mixed with some calling the entry point less attractive after the rally, while others see continued upside potential from supply disruptions and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
